China Expands R&D Super-Deduction to 120% for AI and Biotech: Key Takeaways for Foreign Executives

China’s Ministry of Finance and State Taxation Administration jointly announced on March 25, 2024, that the research and development (R&D) super-deduction rate will rise from the standard 100% to 120% for qualifying enterprises in artificial intelligence (人工智能, réngōng zhìnéng) and biotechnology (生物技术, shēngwù jìshù) sectors, effective retroactively from January 1, 2024. This means that for every RMB 1 million spent on eligible R&D activities, companies can deduct RMB 1.2 million from their taxable income — a direct cash flow benefit that could reduce effective corporate income tax (CIT) liability by up to 30% for a profitable 外商独资企业 (WFOE, wàishāng dúzī qǐyè) operating in these fields.

This policy update is part of a broader push to make China a global innovation leader by 2035. For foreign investors evaluating China market entry, the change introduces a significant cost advantage for R&D-heavy subsidiaries. However, strict eligibility criteria and evolving documentation requirements mean that not every company will qualify automatically. Below, we unpack the key numbers, sector impacts, and practical compliance steps for foreign executives.

Policy Core: What Changes and Who Qualifies

The R&D super-deduction policy has existed since 2008, initially offering a 50% extra deduction (150% total) until 2017, then gradually reduced. The current standard rate is 100% (200% total deduction) for all manufacturing and technology enterprises. The new 120% rate (220% total deduction) targets two priority sectors: AI (including machine learning, natural language processing, and computer vision) and biotechnology (including drug discovery, gene editing, and synthetic biology).

Key eligibility conditions include: (1) the R&D activity must be conducted in China by a resident enterprise (including WFOEs); (2) the activity must be classified as “creative” rather than routine improvement; and (3) the enterprise must maintain detailed project records, including 研发支出辅助账 (R&D expenditure auxiliary ledger, yánfā zhīchū fǔzhù zhàng) for all expenses. Foreign-funded enterprises that hold 高新技术企业 (High and New Technology Enterprise, gāoxīn jìshù qǐyè) certification may already enjoy a 15% reduced CIT rate; these firms can stack the 120% super-deduction for additional benefit.

For a foreign biotech firm with annual R&D spend of RMB 20 million, the 120% rate translates to an additional RMB 200,000 in tax savings per year compared to the 100% rate. For AI startups, where R&D often accounts for 60-80% of total costs, this can meaningfully improve net margins by 2-4 percentage points in early years.

Impact on Foreign-Invested Enterprises in AI and Biotech

The update particularly benefits three types of foreign entities: (1) WFOEs that conduct in-house R&D for the China market; (2) 合资企业 (joint ventures, hézī qǐyè) with a Chinese partner that owns the IP; and (3) regional headquarters that allocate global R&D budgets to China-based teams. The policy does not apply to R&D conducted offshore — only activities physically performed in mainland China qualify.

China’s biotech sector has seen foreign investment rise from USD 4.2 billion in 2020 to USD 7.8 billion in 2023, according to the China Association of Enterprises with Foreign Investment. The 120% super-deduction could accelerate this growth by reducing the after-tax cost of local R&D by approximately 18% for a qualifying entity. For AI, where China already produces nearly 30% of global AI research papers, the policy aligns with the government’s ambition to lead foundational AI model development by 2030.

One caveat: enterprises must maintain a clear paper trail. The tax authorities have become more aggressive in auditing R&D claims since 2022, rejecting 12-15% of super-deduction applications on technical grounds. Common issues include insufficient description of the “creative” nature of the work, failure to separate R&D and production costs, and lack of third-party technical validation for project outcomes.

Pitfalls to Avoid When Claiming the 120% Super-Deduction

Decision Framework: Should Your Company Restructure R&D to Qualify?

Decision Framework: If your company already has a China-based R&D team and is conducting work in AI or biotech with a clear “creative” element (e.g., developing a novel drug candidate or training a new foundation model), the 120% super-deduction is almost certainly worth pursuing. If your R&D is primarily offshore with only local testing or validation activities, restructuring to bring core R&D to China could unlock the benefit — but only if you are willing to invest in local staffing and IP management. If your company is in a related field (e.g., medical devices or energy tech) that is not explicitly listed, the standard 100% rate still applies but may be elevated by future expansion — monitor MOF announcements quarterly.

For foreign execs with limited in-house tax expertise, the safest path is to conduct a one-time eligibility review with a China-based tax firm experienced in R&D incentives. This review should cover: (1) whether your activities meet the “creative” test; (2) whether your expense categorization aligns with the State Administration of Taxation’s 2023 guidance; and (3) whether your documentation pipeline can sustain a potential audit.

NEXT STEPS

1. Review your China R&D structure: Evaluate whether your WFOE or JV can qualify for the 120% rate. Read our guide: China Tax Compliance for Foreign Companies for a full breakdown of CIT incentives and filing requirements.
2. Audit your current R&D expense documentation: Ensure all project files include Chinese auxiliary ledgers, technical descriptions, and proof of “creative” outcomes. Use our template: R&D Expense Documentation Checklist for WFOEs.
3. Engage a local tax specialist: Given the audit risk, we recommend a pre-filing review. Contact our partner network: China Tax Advisory Partners for Foreign Enterprises.

— China Gateway 360 —
Remote China market entry support, built around execution.